

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

# Single Technology Appraisal

# Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer ID6368

## **Provisional Stakeholder List**

Consultees	Commentators (no right to submit or
	appeal)
Company	General
Roche (alectinib)	<ul> <li>All Wales Therapeutics and Toxicology Centre</li> </ul>
Patient/carer groups	Allied Health Professionals Federation
ALK Positive UK	Board of Community Health Councils in
Asthma and Lung UK	Wales
Black Health Agency for Equality	British National Formulary
Cancer Black Care	Care Quality Commission
Cancer Equality	Department of Health, Social Services
Cancer52	and Public Safety for Northern Ireland
Helen Rollason Cancer Charity	Healthcare Improvement Scotland     Madiainage and Healthcare products
Independent Cancer Patients Voice	Medicines and Healthcare products     Populatory Agoney
Macmillan Cancer Support	<ul><li>Regulatory Agency</li><li>National Association of Primary Care</li></ul>
<ul> <li>Maggie's Centres</li> <li>Marie Curie</li> </ul>	<ul> <li>National Association of Finnary Care</li> <li>National Pharmacy Association</li> </ul>
_	<ul> <li>NHS Confederation</li> </ul>
<ul> <li>Oncogene-Driven Lung Cancer Patient Alliance</li> </ul>	<ul> <li>Scottish Medicines Consortium</li> </ul>
<ul> <li>Roy Castle Lung Cancer Foundation</li> </ul>	<ul> <li>Welsh Government</li> </ul>
<ul> <li>Ruth Strauss Foundation</li> </ul>	<ul> <li>Welsh Health Specialised Services</li> </ul>
<ul> <li>South Asian Health Foundation</li> </ul>	Committee
<ul> <li>Specialised Healthcare Alliance</li> </ul>	
<ul> <li>Tenovus Cancer Care</li> </ul>	Possible comparator companies
UK Lung Cancer Coalition	<ul> <li>Aspire Pharma (pemetrexed)</li> </ul>
	<ul> <li>Bristol Myers Squibb (paclitaxel)</li> </ul>
Healthcare professional groups	• Dr Reddy's Laboratories (pemetrexed)
Association of Cancer Physicians	Eli Lilly (pemetrexed)
Association of Respiratory Nurse	Genus Pharmaceuticals (pemetrexed)
Specialists	Medac (oxaliplatin)
British Geriatrics Society	Merck Sharp & Dohme UK
<ul> <li>British Institute of Radiology</li> </ul>	(pembrolizumab)
British Oncology Pharmacy	• Pfizer (cisplatin, carboplatin, docetaxel,
Association	oxaliplatin, paclitaxel, pemetrexed)
British Psychosocial Oncology Society	Ranbaxy (oxaliplatin)
British Thoracic Oncology Group	Roche (atezolizumab)
British Thoracic Society	<ul> <li>Sandoz (cisplatin, pemetrexed)</li> </ul>
Cancer Research UK	

Provisional stakeholder list for the evaluation of alectinib for adjuvant treatment of ALK-positive nonsmall-cell lung cancer ID6368

Issue date: January 2024

© National Institute for Health and Care Excellence 2024. All rights reserved.

Consultees	Commentators (no right to submit or appeal)
<ul> <li>Lung Cancer and Mesothelioma Clinical Expert Group</li> <li>Lung Cancer Nursing UK</li> <li>National Heart and Lung Institute</li> <li>Primary Care Respiratory Society UK</li> <li>Royal College of General Practitioners</li> <li>Royal College of Nursing</li> <li>Royal College of Pathologists</li> <li>Royal College of Physicians</li> <li>Royal College of Radiologists</li> <li>Royal College of Radiologists</li> <li>Royal Pharmaceutical Society</li> <li>Royal Society of Medicine</li> <li>Society and College of Radiographers</li> <li>UK Clinical Pharmacy Association</li> <li>UK Oncology Nursing Society</li> </ul>	<ul> <li>appeal)</li> <li>Seacross Pharmaceuticals (paclitaxel, oxaliplatin, docetaxel)</li> <li>Teva UK (paclitaxel)</li> <li>Zentiva (pemetrexed)</li> <li>Relevant research groups</li> <li>British Association of Lung Research</li> <li>Cochrane Airways Group</li> <li>Cochrane Lung Cancer Group</li> <li>Genomics England</li> <li>Institute of Cancer Research</li> <li>MRC Clinical Trials Unit</li> <li>National Institute for Health Research</li> <li>Associated Public Health groups</li> <li>Public Health Wales</li> </ul>
Others	UK Health Security Agency
<ul><li>Department of Health and Social Care</li><li>NHS England</li></ul>	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

## **Definitions:**


### **Consultees**

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

### **Commentators**



Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.